Good catch, ghmm! This is a notable trial design insofar as BI is sticking with ribavirin in all trial arms. I presume BI has replicon data showing that the BI 207127 + BI 201335 combination is strongly boosted by ribavirin.
The clinicaltrials.gov entry says, “Study First Received: May 3, 2010,” which explains why BI’s program is not included in #msg-51233708.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.